PER percheron therapeutics limited

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-155

  1. 99 Posts.
    lightbulb Created with Sketch. 30
    Hi all, I've been a PER holder since late 2020. Not as long as some but still a reasonable timeframe. There's one point I've never fully understood with respect to the results ANP achieved in the 2A pilot study. All 9 non-ambulant boys were treated with 1102 and we've all seen the beautiful table with green boxes showing improvement in nearly every measure taken. Question: are these results the average of all 9 boys? If so, did some participants see no improvement but their results were off-set by a few who had exceptional results? Can anyone clarify? It would be good if we knew the results for each of the nine participants, or results were communicated in a complete or partial response format.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
0.001(5.00%)
Mkt cap ! $11.96M
Open High Low Value Volume
1.2¢ 1.3¢ 1.1¢ $187.3K 15.66M

Buyers (Bids)

No. Vol. Price($)
14 8891394 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 2178233 6
View Market Depth
Last trade - 11.55am 26/06/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.